

## Alan Lerner, MD



**University Hospitals**  
**3619 Park East Drive #211**  
**Beachwood, OH 44122**  
**Phone: (216) 464-6412**  
**Fax: (216) 464-6403**

**E-mail:**  
**Alan.Lerner @ Uhhospitals.org**

### **CURRENT POSITION:**

**Director, Memory and Cognition Center**  
**University Hospitals Case Medical Center**

### **EDUCATION & TRAINING:**

#### Education

- |           |  |                               |
|-----------|--|-------------------------------|
| 1975-1979 | Cornell University, College of Agriculture and Life Sciences | BS, Biological sciences, 1979 |
| 1981-1983 | Columbia University, College of General Studies              |                               |
| 1983-1984 | SUNY - Downstate Medical School                              |                               |
| 1984-1987 | Cornell University Medical College                           | MD, May 1987                  |

#### Postgraduate Training

- |           |  |
|-----------|--|
| 1987-1988 | Internship, Internal Medicine, Lenox Hill Hospital New York, NY            |
| 1988-1991 | Residency, Department of Neurology, University Hospitals of Cleveland      |
| 1991-1993 | Fellowship, Alzheimer disease/Geriatrics, University Hospital of Cleveland |

#### Thesis Defense Committee

Jonathan Tedesco – Department of Chemistry, Case Western Reserve University, June 2008

### **PROFESSIONAL EXPERIENCE:**

#### Academic

- |                |  |
|----------------|--|
| 1979-1983      | Research Assistant / Computer Programmer; Department of Pediatrics; The New York Hospital - Cornell Medical Center   |
| 1983-1984      | Teaching Assistant, Department of Biology Columbia University, New York  |
| 1992-1998      | Guest Lecturer, Ohio College of Podiatric Medicine, Cleveland, OH<br>Director, Division of Neurology, Department of Medicine Saint Luke's Medical Center, Cleveland, OH  |
| 1993-1997      | Director, Division of Neurology, Department of Medicine Saint Luke's Medical Center, Cleveland, OH   |
| 1994-2001      | Assistant Professor of Neurology, Case Western Reserve University School of Medicine, Cleveland, OH  |
| 2001-2001-2005 | Associate Professor of Neurology, CWRU School of Medicine, Cleveland, OH<br>Chief, Neurology, Heather Hill Hospital, Health and Care Center; Chardon, OH<br>Interim Chief, Physical Medicine and Rehabilitation, Heather Hill Hospital |
| 2001-2003      | Chief of Staff, UHHS/Heather Hill Hospital   |
| 2003-2005      | Director, University Memory and Aging Center, University Hospitals of Cleveland, Cleveland, OH   |
| 2006-          | Director, Memory and Cognition Center, Neurological Institute, University Hospitals Case Medical Center  |

2007- Neurological Institute Chair in Memory and Cognition  
2009- Professor of Neurology, CWRU School of Medicine, Cleveland, OH

**Non-Academic**

1991-1992 Active Staff, Division of Neurology; Department of Medicine Mount Sinai Hospital, Cleveland, OH  
1993-1997 Consultant - Clinical Drug trials Alzheimer Center, University Hospitals of Cleveland- Case Western Reserve University  
1991-1996 Neurology Practice Alan J. Lerner, MD (sole proprietorship) Cleveland, OH  
1999-2001 Medical Director, Clarebridge of Bainbridge, Alterra, Inc. Bainbridge, OH

**BOARD CERTIFICATION:**

November 1992 – American Board of Psychiatry and Neurology

**HOSPITAL AFFILIATIONS:**

1993-1997 Saint Luke's Hospital, Cleveland, OH  
1994- University Hospitals of Cleveland, Cleveland, OH  
2001-2006 Heather Hill Hospital, Chardon, OH  
2001-2005 UHHS- Geauga Regional Hospital, Chardon, OH

**HONORS AND AWARDS:**

Dean's list – Cornell University  
New York State Regent's scholarship for Medical School  
NIH summer research fellowship  
Ray A. Ciszek Service Award from CAAD/AAALF  
Neurological Institute chair in memory and cognition

**PROFESSIONAL SOCIETIES:**

1989 – American Academy of Neurology  
1991 - Behavioral Neurology Society  
1992 – Society for Neuroscience  
1992 - International Brain Research Organization  
1995–1997 International Society for the Investigation of Stress

**HOSPITAL COMMITTEES:**

1995-1997 Stroke Care Guidelines Committee, Saint Luke's Medical Center  
1997 Detoxification Guidelines Committee, Saint Luke's Medical Center  
1999 Rapid Clinical Design Committee - Future Competitive Initiatives, UHC  
1999-2001 Interim Medical Director, Inpatient Rehabilitation Center, UHC  
2000 Web site developer for Inpatient Rehabilitation Center  
2000 UHHS Managing care and quality council  
2001-2005 Heather Hill medical executive committee  
2002-2004 Utilization Review Committee (Chair), UHHS/Heather Hill  
2004-2005 Joint Ethics Committee UHHS/Heather Hill and Geauga Regional Hospital

**EDITORIAL BOARDS:**

2000-2001 Journal of Alzheimer's Disease, Associate Editor  
2002-2007 Alzheimer's Disease and Associated disorders  
2008- Journal of Alzheimer's Disease, Associate Editor

**AD HOC REVIEWER:**

Acta Neurologica Scandinavica  
Alzheimer's disease and Associated disorders: An International Journal  
The American Journal of Medicine  
Annals of Neurology  
Archives of Neurology  
CNS Drugs  
General hospital psychiatry  
JAMA  
Journal of Alzheimer's disease  
Journal of Gerontology  
Journal of Neurology, Neurosurgery and Psychiatry

**ADVISORY COUNCILS & PROFESSIONAL SERVICE:**

- 1993- 2009 Professional advisory board Alzheimer Association, Cleveland area chapter
- 1993- Speaker's Bureau, Alzheimer Association, Cleveland chapter
- 2000-2003 American Federation for Aging Research, National Scientific Advisory Board
- 2002-2005 Drug safety Monitoring Committee, Pioglitazone in the treatment of Alzheimer's Disease (D. Geldmacher, PI/NIA)
- 2002-2006 Lay advisory committee, Medical Goals in Dementia: Ethics and Quality of Life Project (P. Whitehouse, PI; NIA AG17511-01A1)
- 2006- Steering Committee, Alzheimer's disease Cooperative Study (P Aisen, PI/NIA)
- 2006- Steering Committee, Alzheimer's Disease Neuroimaging Initiative (ADNI) (M. Weiner, PI/NIA)

**GRANT REVIEWS:**

Center for aging and health, CWRU Ligue Européenne contre la maladie D'Alzheimer
---

**GRANTS & SPONSORED RESEARCH:**

Principal Investigator

Site Principal Investigator

1. Acute phase reaction and endocrine response to influenza vaccination in Alzheimer's disease and healthy aging (University Hospitals, CWRU) 1992 - 1993.
2. Biochemical screening pilot study (Pfizer) 1993.
3. A double blind, placebo controlled, multi-center study to examine the safety and efficacy of selegiline and alpha - tocopherol in Alzheimer's disease (phase III, NIA / Clinical Study Group Consortium) 1992 - 1997.
4. A multi-center double-blind, placebo controlled study of acetyl-L-carnitine in patients with age defined (between 45 and 65) Alzheimer's disease (phase III, Sigma Tau) 1996 – 1998.
5. A 24-week, double blind, placebo controlled, parallel group, fixed dose study of the efficacy and tolerability of SKB 202026 25 micrograms and 50 micrograms per day in patients suffering from dementia of the probable Alzheimer's type (protocol 202026/045, phase III, Smith Kline Beecham) 1996 - 1998.
6. An open extension study of the long term safety and efficacy of SB 202026 (25 micrograms or 50 micrograms bid) in patients suffering from dementia of the probable Alzheimer's type (protocol 202026/050, extension to study 202026/045 phase III, Smith Kline Beecham) 1996 - 1998.
7. A multi-center placebo-controlled trial of melatonin for sleep disturbance in Alzheimer's disease (NIA /Clinical Study Group Consortium) 1997 – 2000.
8. Efficacy and safety of 6, 12, 24 and 36 mg orally three times daily and 36 mg orally twice daily talsalclidine for 12 weeks in a double blind, randomized, placebo-controlled parallel group comparison in patients with mild to moderate dementia of the Alzheimer's type (phase II, Boehringer Ingelheim) 1998.
9. A multi-center double-blind, placebo controlled study of estrogen replacement therapy in patients with mild to moderate Alzheimer's disease (NIA / Clinical Study Group Consortium) 1998 – 2000.
10. A randomized, double-blind, placebo-controlled trial to evaluate the safety and efficacy of Vitamin E and donepezil HCl (Aricept) to delay clinical progression from mild cognitive impairment to Alzheimer's disease (NIA / Clinical Study Group Consortium) 1998 –2004.
11. A twenty-four-week, multi-center, parallel-group, double-blind, placebo-controlled study of the efficacy, tolerability and safety of estrogen in the treatment of Alzheimer's disease in outpatient women treated with donepezil (Pfizer Inc., E-0401) 1998 – 2000.
12. A multicenter trial of rofecoxib and naproxen in Alzheimer's disease (NIA / Clinical Study Group Consortium) 1999 – 2000.
13. Genetic epidemiological studies of Alzheimer's disease (Cleveland site) (NIA / MIRAGE Consortium.) (L. Farrer, PI, Boston University) 2002-2007.
14. A randomized double - blind, placebo controlled dose-ranging study of the efficacy and tolerability of SB 202026 in patients suffering from dementia of the probable Alzheimer's type (protocol SB202026/005, phase IIB, Smith Kline Beecham) 1995 - 1996.
15. An open label administration of SB 202026 in patients suffering from probable dementia of the Alzheimer's type (protocol 202026/007, phase IIB, Smith Kline Beecham) 1996 - 1997.
16. Evaluation of the safety, tolerability and impact on biomarkers of antioxidant treatment of mild to moderate

- Alzheimer's disease (protocol ADC-025) (NIA / Clinical Study Group Consortium) 2006-2007.
17. A randomized, double-blind, placebo-controlled trial of valproate in Alzheimer's disease (protocol ADC-022) (NIA / Clinical Study Group Consortium) 2003-2008.
  18. Alzheimer's disease neuroimaging initiative (NIA / Clinical Study Group Consortium) 2006-2010.
  19. A one-year, multi-center, randomized, double-blind, placebo-controlled evaluation of the efficacy and safety of donepezil hydrochloride in subjects with mild cognitive impairment (protocol E2020-A001-412) (Eisai – Pfizer) 2004-2006.
  20. A phase III study of the efficacy and safety of Alzhemed™ in patients with mild to moderate Alzheimer's disease (Neurochem) 2005-2007.
  21. An open-label extension of the phase III study of CL-758007 with Alzhemed™ in patients with Alzheimer's disease (Neurochem) 2006-2008.
  22. An open-label multi-center study to assess the safety of AVP-923 (dextromethorphan/quinidine) in the treatment of patients with pseudobulbar affect (Avanir) 2004-2007
  23. A multicenter trial of Vitamin E in aging persons with Down's syndrome (NIA) 2006-
  24. A 24 week double-blind, double-dummy, randomized, parallel-group study to investigate the effects of rosiglitazone(extended release tablets), donepezil, and placebo as monotherapy on cognition and overall clinical response to APOE e4 stratified subjects with mild to moderate Alzheimer's disease (REFLECT-1) (Glaxo) 2007-2008
  25. A Randomized, Double-Blind, Placebo-Controlled Study Using a Bayesian Adaptive Design to Evaluate the Efficacy and Safety of ABT-089 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors (Abbott) 2008-2009
  26. Genetics of Alzheimer's disease in Israeli Arabs (5R01AG017173-07); Principal Investigator 3/01/2008-
  27. A Prospective, Randomized, Multi-Center, Double-Blind, 26 Week, Placebo-Controlled Trials of Memantine (10mg BID) for the Frontal and Temporal Subtypes of Frontotemporal Dementia. (Forest Labs) 2008-
  28. A Phase III, Multicenter, Randomized, Double-blind, Placebo-Controlled, Parallel Group, Efficacy and Safety Trial of bapineuzumab (AAB-001, ELN 115727) in Patients with Mild to Mod Alzheimer's Disease. (Elan) 2008 –
  29. A Randomized, Double-blind, Placebo Controlled, Two Dose-Arm Add-On study of the Effectiveness of Immune Globulin Intravenous (Human), 10% (IVIG, 10%) for the Treatment of Mild to moderate Alzheimer's Disease. (NIA/ADCS Baxter) 2009-
  30. A Double-Blind, Placebo-Controlled, Randomized, Multi-center Study Evaluating the Efficacy and Safety of Eighteen Months of Treatment with PF-04494700 (TTP 488) in Participants with Mild-to-Moderate Alzheimer's Disease (NIA/ADCS Pfizer) 2008-
  31. Double-Blind, Parallel-Group Comparison of 23 mg Donepezil Sustained Release to 10 mg Donepezil Immediate Release in Patients with Moderate to Severe Alzheimer's Disease (Eisai) 2008.
  32. CONCERT (Protocol #DIM18): A Phase 3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Twelve-Month Safety and Efficacy Study Evaluating Dimebon in Patients with Mild-to-Moderate Alzheimer's Disease on Donepezil (Medivation) 2009-
  33. SPRINT-MIND substudy of SPRINT (Systolic pressure reduction intervention trial), Cleveland clinical center network, NHBLI (J. Wright/PI, Cleveland, CCN) 2009-

#### Co-Investigator

1. The effects of cigarette smoking on the development of Alzheimer's disease: epidemiological, clinical, and neurobiological studies (Philip Morris, U.S.A.) 1991 - 2000.
2. National Institute of Aging, Alzheimer Disease Research Center, Clinical Core, University Hospitals of Cleveland Alzheimer Center 1991 – 1993, and 2000 – 2005.
3. A randomized placebo controlled study of DuP 996 90 and 120 mg daily in patients with mild to moderate dementia of the Alzheimer type, USA Study (phase III, DuPont Merck Co.)1991 - 1993.
4. A placebo-controlled study of acetyl-L-carnitine in patients with Alzheimer's disease: a multi-center study. (phase III, Sigma - Tau Corp.) 1991 - 1993.
5. Cerebrospinal fluid studies in Alzheimer's disease (University Hospitals, CWRU) 1992 - 1993.
6. Circadian characteristics of Alzheimer's disease (University Hospitals, CWRU) 1992.
7. A multi-center study of new treatment efficacy instruments for Alzheimer disease clinical trials (NIA / Clinical

Study Group Consortium)1994 - 1995.

8. Fifteen week multi-center, randomized, double-blind, placebo controlled evaluation of the safety and efficacy of E 2020 in patients with Alzheimer disease. (Phase III, Eisai of America) 1996 -1997.
9. Genetic and familial studies in Alzheimer's disease (Philip - Morris, USA). 1993 – 2000.
10. A multi-center double-blind, placebo controlled study of estrogen replacement therapy in patients with mild to moderate Alzheimer's disease (NIA / Clinical study group consortium). 1995 - 2000.
11. A preliminary, double blind, study evaluating the effect of E2020 on visuospatial attention in patients with Alzheimer's disease (Eisai, America) 1996 - 1999.
12. An open-label study to evaluate the safety and efficacy of 1.5 mg. b.i.d. (3 mg/day) through 6 mg. b.i.d. (12 mg/day) of Exelon® in patients with mild to severe probable Alzheimer's disease in the community setting (Novartis, ENAB-356) 1997 – 2000.
13. A Randomized Double-Blind Placebo-Controlled Trial Of The Effects Of Docosahexaenoic Acid (DHA) In Slowing The Progression Of Alzheimer's Disease (NIA/ADCS) 2007-2009

#### **INVITED PRESENTATIONS:**

1. Neurology of Albinism, Neuroscience Grand Rounds, University Hospitals of Cleveland, Cleveland, OH, February 14, 1991.
2. Acute Phase Reactants in Alzheimer's Disease, Neuroscience Grand Rounds, The New York Hospital - Cornell Medical Center, New York, NY, May 20, 1994.
3. Alzheimer's disease drug trials: An American Perspective, St James Hospital, Dublin, Ireland March 28, 1996.
4. Alzheimer's Disease Evaluation and Management, 20th Annual Medicine Update, Association of Philippine Physicians in Ohio, Cleveland, OH April 12, 1997.
5. Alzheimer' Disease Management Allen County Medical Society, Lima, OH September 16, 1997
6. Alzheimer's disease Update Medical Grand Rounds, Saint Luke's Medical Center, June 24, 1998
7. Case Presentation, Neuroscience Grand Rounds, University Hospitals of Cleveland, October 2, 1998
8. Treatment of dementia. Western Reserve Geriatric Education Center, January 14, 1999
9. Dementia – Diagnosis and Therapy. Western Reserve Geriatric Education Center. March 31, 1999
10. Case Presentation, Neuroscience grand Rounds, University Hospitals of Cleveland, September 17, 1999.
11. Recognition and Treatment of Dementia, Western Reserve Geriatric Education Center, October 28, 1999
12. Down's Syndrome and Alzheimer's disease. The Metzenbaum Center, Chesterland, OH, December 1999
13. Ethics and the End of Life. Alzheimer's Association, Cleveland Chapter, May 16, 2000
14. Mini-Med School: Windows on the Mind: Alzheimer's disease, May 17, 2000
15. Clinical endocrine aspects of Alzheimer's disease Invited Participant – 1<sup>st</sup> Virtual Congress of Endocrinology – December 2000.
16. New Treatments for Alzheimer's disease. Neurology Grand Rounds, University of Louisville School of Medicine, October 16, 2000.
17. Neuroendocrine aspects of cognition across the life span. Cleveland Neuropsychological Society. January 3, 2001
18. Treatment of Alzheimer's disease: New approaches. Medicine Grand Rounds, Saint Elizabeth's Hospital, Youngstown, OH 1/09/2001
19. Caring for your elderly patient; Update on Alzheimer's disease. Promedica Health System, Toledo, OH March 8, 2001
20. Neuroendocrine aspects of Alzheimer's disease. Family practice Grand Rounds, Flower Hospital, Toledo, OH March 8, 2001
21. Memory, activity and Alzheimer's disease. Research symposium of the Council on Aging and Adult development, American Association for Active Lifestyles and Fitness (AAALF). Cincinnati, OH, March 30, 2001
22. Post-Acute care. Neuroscience grand rounds, University Hospitals of Cleveland, April 27, 2001
23. Alzheimer's disease: What's New? Konferencija "Šiuolaikiniai Alzheimerio ligos diagnostikos ir gydymo ypatumai", Klaipeda, Lithuania, June 22, 2001
24. Spinal cord compression in Non-Hodgkin's Lymphoma. Neuroscience grand rounds, University Hospitals of Cleveland, September 21, 2001
25. Neuropathic Pain. Orthopaedic Update, UHHS/Geauga Regional Hospital, October 17, 2001.
26. Issues in Stroke Rehabilitation, Heather Hill Hospital, October 19, 2001
27. Neurorehabilitation. 3<sup>rd</sup> Annual Neurology for Non-Neurologists Course , Cleveland, OH, November 10, 2001

28. Mental Status Testing. Western Reserve Education Center, November 12, 2001
29. Treatment of Alzheimer's disease. Geriatrics symposium: Parma General Community Hospital, Parma Heights, OH February 13, 2002
30. Whither the PEG tube? Neuroscience grand rounds, University Hospitals of Cleveland, April 18, 2005
31. Normal Pressure Hydrocephalus. The Aging Brain. Cleveland Clinic Continuing Education Course. Cleveland, OH November 10, 2005.
32. Vascular Dementia. First Annual Cleveland Stroke Conference. Case Western Reserve University, November 30, 2005
33. Adventures in homocysteine. Neuroscience Grand Rounds, University Hospitals of Cleveland, December 9, 2005
34. Treatment of Alzheimer's disease. Primary Care Symposium, Neurology update. Lake Hospital system, Eastlake, OH January 25, 2006
35. Treatment of Alzheimer's disease. An Alzheimer's disease update. Firelands Regional Medical Center, School of Nursing, March 3, 2006
36. Drug Therapy for Dementia. Ohio Department of Health: Division of Quality Assurance Dementia Conference. Columbus, OH , April 3, 2006
37. Alzheimer's disease: Fact and Mythos. Northern Ohio Association of Pharmacists, Cleveland, OH October 25, 2006
38. Alexia without Agraphia. Neuroscience Grand Rounds, University Hospitals Case Medical Center. January 19, 2007
39. Development of diagnostic criteria. 5th Annual MCI symposium, Miami Beach, FL April 14, 2007
40. Creativity and the brain. Keynote address. Art therapy studio symposium. Cleveland Museum of Art, September 14, 2007.
41. What is Alzheimer's disease? Representing dementia and breaking through the middle ground. The value and importance of art in health care. Museum of Modern Art, New York, New York. March 7, 2008
42. Dementia update. Parma community general hospital. April 23, 2008.
43. Dementia diagnosis and treatment. Intercontinental Hotel, Cleveland Clinic Foundation, April 30, 2008.
44. Studies in Category Fluency, Neuroscience Grand Rounds, University Hospitals Case Medical Center. December 12, 2008
45. Use of medications in Alzheimer's disease: Association of race and demographic variables. Fairfax community development center, Cleveland, OH sponsored by Cleveland CTSC. July 16, 2009
46. Dementia and Epilepsy. Epilepsy grand rounds, University Hospitals Case Medical Center. August 31, 2009

## **BIBLIOGRAPHY:**

### Original Articles

1. Levine LS, Dupont B, Lorenzen F, Pang S, Pollack M, Oberfield S, Kohn B, Lerner A, Cacciari E, Mantero F, Cassio A, Scaroni C, Chiumello G, Rondanini GF, Gargantini L, Giovannelli G, Virdis R, Bartolotta E, Migliori C, Pintor C, Tato L, Barboni F, New MI: Cryptic 21-hydroxylase deficiency in families of patients with classical congenital adrenal hyperplasia. *Journal of Clinical Endocrinology and Metabolism* 51:1316 - 1324, 1980.
2. Levine LS, Dupont B, Lorenzen F, Pang S, Pollack M, Oberfield SE, Kohn B, Lerner A, Cacciari E, Mantero F, Cassio A, Scaroni C, Chiumello G, Rondanini GF, Gargantini L, Giovannelli G, Virdis R, Bartolotta E, Migliori C, Pintor C, Tato L, Barboni F, New M. Genetic and hormonal characterization of cryptic 21-hydroxylase deficiency. *Journal of Clinical Endocrinology and Metabolism* 53:1193 - 1198, 1981.
3. Kohn B, Levine LS, Pollack MS, Pang S, Lorenzen F, Levy D, Lerner AJ, Rondanni GF, Dupont B, New MI. Late onset steroid 21-hydroxylase deficiency: A variant of classical congenital adrenal hyperplasia. *Journal of Clinical Endocrinology and Metabolism* 55:817-827, 1982.
4. New MI, Lorenzen F, Lerner AJ, Kohn B, Oberfield SE, Pollack MS, Dupont B, Stoner E, Levy DJ, Pang S, Levine LS: Genotyping steroid 21-hydroxylase deficiency: Hormonal reference data. *Journal of Clinical Endocrinology and Metabolism* 57:320-326, 1983.
5. Pang SY, Lerner AJ, Stoner E, Levine LS, Oberfield SE, Engel I, New MI: Late onset adrenal steroid 3-beta-hydroxysteroid dehydrogenase deficiency. I. A cause of hirsutism in pubertal and postpubertal women. *Journal of Clinical Endocrinology and Metabolism* 60:428 - 439, 1985.
6. Dupont B, Virdis R, Lerner AJ, Nelson C, Pollack MS, New MI: Distinct HLA-B antigen associations for the salt wasting and simple virilizing forms of congenital adrenal hyperplasia due to 21-hydroxylase deficiency. *In* Albert, Baur and Mayr (eds) *Histocompatibility Testing 1984: Report of the 9th International Histocompatibility Workshop*. Springer-Verlag, Berlin, 1984.
7. Friedland RP, Koss E, Lerner A, Hedera P, Jagust WJ, Ellis W, Dronkers N, Ober BA. Functional imaging, the frontal lobes, and dementia. *Dementia* 4:192-203, 1993.

8. Friedland RP, Lerner AJ, Hedera P, Brass EP. Encephalopathy associated with Bismuth Subgallate therapy. *Clinical Neuropharmacology* 16 (2):173-176, 1993.
9. Lerner AJ, Koss E, Patterson MB, Ownby RL, Hedera P, Friedland RP, Whitehouse PJ. Concomitants of visual hallucinations in Alzheimer's disease. *Neurology* 1994; 44:523 - 527.
10. Hedera P, Cohen ML, Lerner AJ, Friedland RP. Dementia preceding motor symptoms in Parkinson's disease: A case study. *Neuropsychiatry, Neuropsychology, and Behavioral Neurology*, 1994; 7:67 - 72.
11. Hedera P, Lai S, Haacke EM, Lerner AJ, Hopkins AL, Lewin JS, Friedland RP. Abnormal connectivity of the visual pathways in human albinos demonstrated by susceptibility sensitized magnetic resonance imaging. *Neurology* 1994; 44:1921 – 1926
12. Hedera P, Lerner AJ, Castellani R, Friedland RP. Concurrence of Alzheimer's disease, Parkinson's disease, diffuse Lewy body disease, and Amyotrophic Lateral Sclerosis. *Journal of the Neurological Sciences*, 1995; 128: 219 -224.
13. Lerner AJ, Koss E, Patterson MB, Ownby RL, Hedera P, Friedland RP, Whitehouse PJ. Concomitants of visual hallucinations in Alzheimer's disease. *Parkinson/Alzheimer Digest*, April 1995.
14. Hedera P, Wu D, Lewin JS, Miller D, Lerner AJ, Friedland RP. Temporal patterns of uncoupling between oxidative metabolism and regional cerebral blood flow demonstrated by functional magnetic resonance imaging. *Investigative Radiology*, 1995; 30:625 - 633.
15. Hedera P, Lai S, Lewin JS, Haacke EM, Wu D, Lerner AJ, Friedland RP. Assessment of cerebral blood flow reserve using functional magnetic resonance imaging. *Journal of Magnetic Resonance Imaging*, 1996, 6: 718 - 725.
16. Lerner AJ, Hedera P, Koss E, Stuckey J, Friedland RP. Delirium in Alzheimer's disease. *Alzheimer's Disease and Associated Disorders*, 1997; 11: 16 - 20.
17. Clark C, Ewbank D, Lerner A, Doody R, Henderson VW, Panisset M, Morris JC, Fillenbaum G, Heyman A and the CERAD collaborators. The Relationship between Extrapyrmidal Signs and Cognitive Performance in Patients with Alzheimer's Disease . *Neurology*, 1997 ; 49: 70 –75
18. Lerner AJ, Koss E, Debanne SM, Rowland DY, Smyth KA, Friedland RP: Interactions of smoking history with estrogen replacement therapy as protective factors for Alzheimer's disease. *Research Letter, Lancet*, February 8, 1997, p. 403 - 404
19. Geldmacher DS, Lerner AJ, Voci JM, Noelker EA, SompleCL, Whitehouse PJ. Treating functional decline in Down's syndrome using selective serotonin reuptake inhibitor drugs. *J Geriatric Psychiatry and Neurology*, 1997, 10:99 – 104
20. Hedera P, Wu D, Collins S, Lewin JS, Miller D, Lerner AJ, Klein S, Friedland RP. Sex and Electroencephalographic after photic stimulation predict signal changes in the visual cortex detected by functional MR images. *American Journal of Neuroradiology*, 19: 853 – 857,1998
21. Lerner AJ. Drug Evaluation: Ebiratide. *Current Research in Alzheimer's Disease*, 3 (4),1998
22. Friedland RP, Farrer LA, Cupples LA, Lerner AJ, and the MIRAGE study group. Smoking and duration of illness in Alzheimer's disease. *Research letter, The Lancet*, 1998
23. Hemingway-Eltomey JM, Lerner AJ: Adverse effects of Donepezil in treating Down's syndrome associated Alzheimer's disease. *The American Journal of Psychiatry*, 1999 156: 1470.
24. Lerner AJ: Women and Alzheimer's disease. *Journal of Clinical Endocrinology and Metabolism*, 1999 84: 1830 – 1834.
25. Lerner AJ: Alzheimer's disease in males: Endocrine aspects and prospects. *Journal of Clinical Endocrinology and Metabolism*, 84: 3416 – 3419, 1999.
26. Lerner AJ, Chen C, Elston R, Friedland RP: Response of the Hypothalamic – Pituitary – Adrenal axis to lumbar puncture stress. *J Alzheimer's disease* 2:193-198, 2000
27. Friedland, RP, Fritsch T, Smyth KA, Koss E, Lerner AJ, Chen CH, Petot GJ, DeBanne SM. Patients with Alzheimer's disease have reduced premorbid activities compared to healthy controls. *Proceedings of the National Academy of Sciences*, 98:3440-3445, 2001
28. Mizrahi EH, Fritsch T, Geldmacher DS, Soas AH, Friedland RP, Lerner AJ. Medication use in Alzheimer's disease and healthy aging: Results from a research registry. *Clinical Gerontologist*, 2002
29. Debanne SM, Petot GJ, Li J, Koss E, Lerner AJ, Riedel TM, Rowland DY, Smyth KA, Friedland RP: On the use of surrogate responders for controls in case-control studies of Alzheimer's disease. *Journal of the American Geriatrics Society*, 49:980-984, 2001
30. Petot GJ, Debanne SM, Riedel TM, Smyth KA, Cook TB, Koss E, Lerner AJ, Friedland RP: Surrogate responders do not introduce bias in a case control study of dietary risk factors for Alzheimer's disease. *American Journal of Nutrition*, 2001
31. Fritsch T, McClendon MJ, Smyth KA, Lerner AJ, Chen CH, Petot GJ, Debanne SM, Soas A, Friedland RP Effects of educational attainment on the clinical expression of Alzheimer's disease: results from a research registry *Am J Alzheimers Dis Other Demen.* 16:369-76, 2001
32. Bhidayasari R, Riley DE, Somers JT, Lerner AJ, Büttner-Ennnever J, Leigh RJ. Pathophysiology of Slow Vertical Saccades in Progressive Supranuclear Palsy. *Neurology* 57:2070-7, 2001.
33. Zaidat OO, Ubogu EU, Lerner AJ: Recurrent Transient Ischemic Attacks as the initial presenting

- manifestation of Type A Aortic Dissection. A Case Report. *Annals of Vascular Surgery*, 2002.
34. Mizrahi EH, Jacobsen DW, Debanne SM, Traore F, Lerner AJ, Friedland RP, Petot GJ. Plasma total homocysteine levels, dietary B6 and folate intake in AD and healthy aging. *Journal of Nutrition, Health and Aging* 7:160-165, 2003.
  35. Ubogu EE, Sagar SM, Lerner AJ, Maddux BN, Suarez JI, Werz MA. Ketamine for refractory status epilepticus: a case of possible ketamine-induced neurotoxicity. *Epilepsy Behav.* 4:70-75, 2003.
  36. Mizrahi EH, Bowirrat A, Jacobsen DW, Korczyn AD, Traore F, Petot GJ, Lerner AJ, Debanne SM, Adunsky A, DiBello PM, Friedland, RP. Plasma homocysteine, vitamin B12 and folate in Alzheimer's patients and healthy Arabs in Israel. *Journal of Neurological Sciences J Neurol Sci* 227:109-113. 2004.
  37. Lindstrom HA, Fritsch T, Petot G, Smyth KA, Chen CH, Debanne SM, Lerner AJ, Friedland RP, The relationships between television viewing in midlife and the development of Alzheimer disease in a case-control study. *Brain and Cognition.* 58:157-65, 2005.
  38. Petot GJ, Vega U, Traore F, Fritsch T, Debanne SM, Friedland RP, Lerner AJ . Height and Alzheimer's disease: Findings from a case-control study. *J Alzheimers Dis.* 11:337-41, 2007.
  39. Fritsch T, McClendon MJ, Smyth KA, Lerner AJ, Friedland RP, Larsen JD Cognitive Functioning in Healthy Aging: The Role of Reserve and Lifestyle Factors Early in Life. *The Gerontologist* 47:307-322, 2007
  40. Lerner AJ, Strauss MI, Sami SA. Apathy in Alzheimer's disease. *Geriatrics.* 62:14-17, 2007.
  41. Lerner AJ. Treatment of Pica behavior with Olanzapine. *CNS Spectrums* 13:19, 2008
  42. Giuffrida JP, Lerner A, Steiner R, Daly J. Upper Extremity Stroke Therapy Task Discrimination Using Motion Sensors and Electromyography. *IEEE Transactions on Neural Systems & Rehabilitation Engineering*, 16: 82-90, 2008
  43. Goodenowe DR, Cook LL , Liu J, Lu Y, Jayasinghe DA, Ahiahonu PWK, Heath D, Yamazaki Y, Wood PL, Krenitsky KF, Sparks DL, Lerner A, Friedland R, Kudo T, Kamino K, Morihara, T, Takeda M, Flax J. Serum Ethanolamine Plasmalogen Levels Correlate with Alzheimer's Pathology and Severity of Dementia *J Lipid Res.* 48:2485-2498, 2007.
  44. Lerner AJ, McClendon MJ, Sami S, Adams K, Ogrocki P, Smyth KA. Factors affecting usage of Memantine in Alzheimer's disease. *Alz. Dis Assoc Disord*, 22:137-143, 2008.
  45. Lerner AJ. Evaluation of memory dysfunction. *Neurological Institute Journal* 1: 12-15, 2008
  46. Grommes C, Downes K, Griffin K, Lerner AJ. Steroid responsive encephalopathy with diffusion MRI changes. *Am J Neuroradiology*, 29: 1550-1551, 2008.
  47. McClendon MJ, Hernandez S, Smyth KA, Lerner AJ. Memantine and Acetylcholinesterase Inhibitor Treatment in Cases of CDR 0.5 or Questionable Impairment. *J Alzheimer's disease* 16:577-83. 2009
  48. Lerner AJ, Ogrocki PK, Thomas PJ. Network graph analysis of category fluency data. *Cognitive and Behavioral Neurology* 22: 45-52, 2009.
  49. Albo Z, Lerner AJ. The role of working memory impairment in ADHD-new therapeutic indications. *J of pre-clinical and clinical research* 2: 1-5, 2008.
  50. Dwyer BE, Zacharski LR, Balestra DJ, Perry G, Smith MA, Lerner AJ, Zhu X. Getting the iron out: Phlebotomy for Alzheimer's disease. *Medical Hypotheses* 72: 504-509, 2009
  51. Hernandez S, McClendon MJ, Zhou X-H A, Sachs M, Lerner AJ. Pharmacological treatment of Alzheimer's disease: Effect of race and demographic variables. *J Alzheimer's disease* 2009 (in press)
  52. Gustaw-Rothenberg KA, Siedlak SL, Bonda DJ, Lerner AJ, Tabaton M, Perry G, Smith MA. Sera dissociated Amyloid- $\beta$  antibody levels during the progression of Alzheimer's disease: A population =based study. *Experimental Gerontology* 2009 (in press)

#### Books

1. *The Little Black Book of Neurology. A manual for Neurologic House Officers*, third edition, Lerner, AJ (ed.). Mosby - Yearbook, Saint Louis, 1994
2. *The Little Black Book of Neurology. A manual for Neurologic House Officers*, Fourth edition, Zaidat, OO and Lerner, AJ (ed.). Harcourt health Sciences, Philadelphia, 2002
3. *Diagnostic Criteria in Neurology*. Lerner, AJ(ed). Humana Press, 2006
4. *The Little Black Book of Neurology. A manual for Neurologic House Officers*, Fifth edition, Zaidat, OO and Lerner, AJ (ed.).Harcourt Health Sciences, Philadelphia, 2008

#### Book Chapters & Review Articles

1. New MI, Dupont B, Lorenzen F, Pang S, Pollack MS, Oberfield SE, Kohn B, Lerner A, Cacciari E, Mantero F, Cassio A, Scaroni C, Chiumello G, Rondanini GF, Gargantini L, Giovannelli G, Virdis R, Bartolotta E, Migliori C, Pintor C, Tato L, Barboni F, Levine LS: Recognition of allelic variants of 21-hydroxylase deficiency by HLA genotyping - hormonal and clinical evaluation. *In* Chiumello G and Sperling M (eds), *Recent Progress in Pediatric Endocrinology*. Raven Press, New York, 1983.
2. Whitehouse P, Lerner A, Hedera, P: Dementia. *In* Valenstein E and Heilman K (eds) *Clinical Neuropsychology*, third edition, Oxford University Press, 1993
3. Lerner A, Whitehouse P: Primary Dementias. *In* Albert M (ed) *Clinical Neurology of Aging*. Oxford Press, New

York, 1994.

4. Lerner A, Hedera P, Whitehouse P: Alzheimer's Disease. *In* Rakel R (ed), *Conn's Current Therapy* 1995. W.B. Saunders, New York 1995.
5. Lerner AJ, Strauss ME, Whitehouse PJ: Neuropsychiatric aspects of degenerative dementias associated with motor dysfunction. *In* Yudofsky S (ed.), *Textbook of Neuropsychiatry*, third edition, APA Press, 1997.
6. Friedland RP, Smyth KA, Rowland DY, Esteban - Santillan C, Koss E, Cole R, Lerner AJ, Whitehouse PJ, Petot G, Debanne SM: Pre-Morbid Activities are reduced in patients with Alzheimer's disease as compared to age- and sex-matched controls: Results of a case-control study. *In* Iqbal K, Winblad B, Nishimura T, Takeda M and Wisniewski HM (ed), *Alzheimer's Disease: Biology, Diagnosis and Therapeutics*, John Wiley and Sons, Ltd., 1997.
7. Lerner AJ, Whitehouse PJ: Neuropsychiatric aspects of degenerative dementias associated with motor dysfunction. *In* Yudofsky S (ed), *Textbook of Neuropsychiatry*, fourth edition, APA Press, 2002.
8. Lerner AJ: Estrogens and SERMS: Clinical aspects of cognition with aging and Neurodegenerative diseases. *In* Manni, A and Verderame, M (eds), *Selective Estrogen Receptor Modulators*, Clinical Endocrinology series, Humana press, 2002.
9. Lerner AJ, Riley D: Neuropsychiatric aspects of degenerative dementias associated with motor dysfunction. *In* Yudofsky SC, Hales RE (ed), *Textbook of Neuropsychiatry*, fifth edition, APA Press, 2007.
10. Lerner AJ, Riley D: Neuropsychiatric aspects of degenerative dementias associated with motor dysfunction. *In* Yudofsky SC, Hales RE (ed), *Essentials of Neuropsychiatry and Behavioral Neurosciences* APA Press, (in press, 2009).
11. Lerner AJ, Schoenberg M. Deconstructing the medical chart. *In* Schoenberg M (ed), *Little Black Book of Neuropsychology*, (in press 2009)
12. Lerner AJ, Schoenberg M. Neuroanatomy and Neurophysiology for Neuropsychologists. *In* Schoenberg M (ed), *Little Black Book of Neuropsychology*, (in press 2009)

#### Abstracts

1. Riley D, Lerner A: How good is our family history of Parkinson's disease? 10th International Symposium on Parkinson's Disease, Tokyo, Japan p. 171, 1991.
2. Lerner A, Koss E, Patterson M, Ownby R, Chatterjee A, Friedland R, Whitehouse P: Visual hallucinations in Alzheimer's disease and the BEHAVE - AD. American Academy of Neurology, San Diego, May 1992. *Neurology* 42(4, suppl 3):140, 1992.
3. Lerner A, Cochran E, Friedland R, Riley D, Whitehouse P, Lanska D, Vick N, Tresser N, Cohen M, Gambetti P. Dementia with pathologic findings of cortical-basal ganglionic degeneration. American Neurologic Association, Toronto, October 1992 *Annals of Neurology*, 32 (2): 271, 1992
4. Debanne SM, Rowland DY, Schnell A, Hedera P, Koss E, Lerner A, Smyth K, Whitehouse P, Friedland R: Issues related to the selection of controls when exposure is related to diagnosis. World federation of Neurology, Research Group on Neuroepidemiology, San Diego, May 1992. *Neuroepidemiology* 11(2):9, 1992.
5. Friedland RP, Smyth KA, Koss E, Schnell A, Lerner A, Hedera P, Petot G, Rowland D, Debanne S. Education and its surrogates as protective factors for Alzheimer's disease (AD): design of a case-control study. World Federation of Neurology, Research Group on Neuroepidemiology, New York, April 1993. *Neuroepidemiology* 12 (2):7, 1993.
6. Petot G, Debanne S, Hedera P, Koss E, Lerner A, Rowland D, Schnell A, Smyth KA, Friedland R. Use of a food frequency questionnaire in a risk factor study of Alzheimer's disease. World Federation of Neurology, Research Group on Neuroepidemiology. New York, April 1993. *Neuroepidemiology* 12:17-18.
7. Lerner A, Cohen DL, Pax R, Friedland R, Kalaria RN. Cell adhesion molecules in the vascular and neocortical pathology of Alzheimer's disease. Society for Neuroscience, Washington DC, November 1993. *Society for Neuroscience Abstracts* 19:623, 1993
8. Hedera P, Lerner AJ, Stuckey J, Friedland RP. Acute confusional states in Alzheimer's disease. Society for Neuroscience, Washington DC, November 1993. *Society for Neuroscience Abstracts* 19:229, 1993.
9. Lerner AJ, Strick N, Lowy M, Hedera P, Friedland RP. Altered hypothalamic-pituitary-adrenal axis responsivity in Alzheimer's disease. American Academy of Neurology, Washington DC, May 1994. *Neurology* 1994; 44 (Suppl 2): A 241.
10. Hedera P, Lai S, Haacke EM, Lerner AJ, Hopkins AL, Lewin JS, Friedland RP. Localization of visual cortical activation using susceptibility sensitized MRI: Studies in albinos and normal subjects. American Academy of Neurology, Washington DC, May 1994. *Neurology* 1994; 44 (Suppl 2): A 266.
11. Lai S, Hedera P, Haacke EM, Lerner AJ, Hopkins AL, Lewin JS, Friedland RP. Functional MRI: A promising approach for the evaluation of visual pathway abnormalities associated with albinism. Proceedings of the Society of Magnetic Resonance in Medicine, San Francisco CA 1994. *Journal of Magnetic Resonance Imaging*, 1994; 4:59.

12. Petot GJ, Debanne SM, Hedera P, Koss E, Lerner AJ, Rowland DY, Schnell AH, Smyth K, Friedland RP. Determination of diet patterns through adult life in a case control study of Alzheimer's disease. Nutritional assessment of elderly populations: Measure and Function. United States Department of Agriculture, Boston MA, October 1993.
13. Geldmacher DS, Lerner AJ, Voci JM, Noelker EA, Somple LC, Whitehouse PJ. Treating functional decline in adults with Down's syndrome. Sixth annual meeting, American Neuropsychiatric Association, 1994.
14. Petot GJ, Debanne SM, Durand E, Hedera P, Koss E, Lerner AJ, Rowland DY, Schnell AH, Smyth K, Friedland RP. Diet patterns during adult life in a case control study of risk factors for Alzheimer's disease: Preliminary data for selected nutrients and food groups. Fourth international conference on Alzheimer's disease and related disorders, Minneapolis, MN, July 1994. *Neurobiology of Aging* 15, Suppl: S47, 1994.
15. Koss E, Debanne S, Durand E, Friedland R, Hedera P, Lerner A, Petot G, Porter C, Rowland D, Schnell A, Smyth K. Relationships between past cigarette smoking status and cognitive function in healthy adults. Fourth international conference on Alzheimer's disease and related disorders, Minneapolis, MN, July 1994. *Neurobiology of Aging* 15, Suppl: S47, 1994.
16. Petot GJ, Debanne SM, Durand E, Hedera P, Koss E, Lerner AJ, Rowland DY, Schnell AH, Smyth K, Friedland RP. Adaptation of the Block food frequency questionnaire to obtain adult life-time dietary patterns from Alzheimer's disease patient surrogates, Controls and controls surrogates. Second International Conference on Dietary assessment methods, 1994.
17. Lerner AJ, Hedera P, Koss E, Stuckey J, Friedland RP. Acute confusional states in Alzheimer's disease. First World Congress on Stress, Bethesda, MD, October 1994.
18. Petot GJ, Feinstein S, DeBanne SM, Koss E, Lerner AJ, Rowland DY, Cole R, Smyth K, Whitehouse PJ, Friedland RP. Preliminary data on diet patterns throughout adult life in a case control study of risk factors for Alzheimer's disease. World Federation of Neurology, North American Neuroepidemiology Meeting, Seattle, WA, May 1995. *Neuroepidemiology* 14(Suppl):7 - 8, 1995.
19. Koss E, Elshaw E, Salipante E, Rowland D, Cole R, Debanne S, Esteban-Santillan C, Hedera P, Lerner AJ, Petot G, Smyth KA, Whitehouse PJ, Friedland RP. Positive relationship between playing a musical instrument and IQ scores in older healthy adults. World Federation of Neurology, North American Neuroepidemiology Meeting, Seattle, WA, May 1995. *Neuroepidemiology* 14 (Suppl): 13, 1995.
20. Lerner AJ, Cole R, Debanne S, Esteban - Santillan C, Hedera P, Koss E, Petot G, Rowland D, Smyth K, Whitehouse PJ, Friedland. Immunological and endocrine conditions in an Alzheimer's disease case-control study. World Federation of Neurology, North American Neuroepidemiology Meeting, Seattle, WA, May 1995 . *Neuroepidemiology* 14 (Suppl):10, 1995.
21. Friedland RP, Smyth KA, Koss E, Esteban - Santillan C, Cole R, Lerner AJ, Hedera P, Durand E, Petot G, Rowland DY, Debanne S. Persons with Alzheimer's disease (AD) engage in fewer premorbid stimulating activities than controls: Results from a case - control study. World Federation of Neurology, North American Neuroepidemiology Meeting, Seattle, WA, May 1995. *Neuroepidemiology* 14 (Suppl): 8, 1995
22. Lerner, AJ, Zakieh N, Hedera P, Davis G, Blum, J. Risk factors for silent cerebral ischemia. *Neurology* 1995 (Suppl 4): A459.
23. Lerner AJ. Gesture as a symbol system: Evidence for left hemispheric dominance in a deaf-mute woman without other language and with a left hemispheric cerebral hemorrhage. Seventh annual meeting of the American Neuropsychiatric association in conjunction with the Behavioral Neurology association, Pittsburgh PA, October 13, 1995. *Journal of Neuropsychiatry* 7(3):405.
24. Lerner AJ, Cole R, Debanne S, Esteban - Santillan C, Hedera P, Koss E, Petot G, Rowland D, Smyth K, Whitehouse PJ, Friedland. Immunological and endocrine conditions in an Alzheimer's disease case-control study. The spectrum of research on aging and the aged, research day 1995. November 2, 1995, Cleveland OH.
25. Petot GJ, Debanne SM, Feinstein SJ, Cole R, Koss E, Lerner AJ, Rowland DY, Smyth K, Whitehouse PJ, Friedland RP. Antioxidant nutrients in adult lifetime diet patterns in a case control study of risk factors for Alzheimer's disease: Preliminary data. The spectrum of research on aging and the aged, research day 1995. November 2, 1995, Cleveland OH.
26. Koss E, Elshaw E, Salipante E, Conaway C, Cole R, Debanne S, Esteban-Santillan C, Lerner AJ, Petot G, Rowland D, Smyth KA, Whitehouse PJ, Friedland RP. Positive relationship between playing a musical instrument and cognitive abilities in older healthy adults. The spectrum of research on aging and the aged, research day 1995. November 2, 1995, Cleveland OH.
27. Esteban - Santillan C, Smyth K, Conaway C, Rowland D, Debanne S, Friedland R, Koss E, Lerner A, Petot G, Whitehouse P. Mental, social and physical demands of jobs as risk factors for Alzheimer's disease. American Academy of Neurology, San Francisco CA, March 1996. *Neurology* 46: Suppl A433 - 434, 1996.
28. Rowland DY, Whitehouse PJ, Rossor M, Roques P, Debanne SM, Koss E, Lerner A, Petot G, Friedland R, Smyth K. Influences on the expression of autosomal dominant Alzheimer's disease: Comparison of methods

- to analyze environmental factors. World Federation of Neurology, North American Neuroepidemiology Meeting, San Francisco, CA, March 1996. *Neuroepidemiology* 1996 (Supplement) 15:18
29. Petot GJ, Cole R, Debanne SM, Koss E, Lerner AJ, Rowland DY, Smyth K, Whitehouse PJ, Friedland RP: Adult lifetime dietary intake patterns of antioxidant nutrients and foods in a case control study of risk factors for Alzheimer's disease: Preliminary data. World Federation of Neurology, North American Neuroepidemiology Meeting, San Francisco, CA, March 1996. *Neuroepidemiology* 1996 (Supplement) 15:13.
  30. Lerner AJ, Koss E, Gilham S, Cole R, Debanne S, Esteban - Santillan C, .Petot GJ, Rowland DY, Smyth KA, Whitehouse PJ, Friedland RP. Estrogen replacement therapy as a protective factor for Alzheimer disease: Interactions with other risk factors. Society for Neuroscience, November 1996. Society for Neuroscience Abstracts 1996, 22:15.
  31. Friedland RP, Smyth KA, Rowland DY, Esteban - Santillan C, Koss E, Cole R, Lerner AJ, Whitehouse PJ, Petot G, Debanne SM. Premorbid activities are reduced in patients with Alzheimer's disease as compared to age and sex matched controls: results of a case-control study. Fifth international conference on Alzheimer's disease and related disorders, Osaka, Japan, July 1996. *Neurobiology of Aging* 17: S122, 1996.
  32. Petot GJ, Cole R, Conaway C, Debanne SM, Esteban-Santillan C, Koss E, Lerner AJ, Rowland DY, Smyth KA, Whitehouse PJ, Friedland RP. Adult lifetime dietary patterns of antioxidant vitamin and carotenoid consumption in a case control study of risk factors for Alzheimer's disease. American Aging Association, San Francisco, CA, October 1996.
  33. Friedland RP, Smyth K, Cole R, Koss E, Lerner AJ, Rowland D, Debanne S. Persons with Alzheimer's disease (AD) have reduced activities in early life. XVI world Congress of Neurology, Buenos Aires, Argentina, September 1997.
  34. Friedland RP, Lerner AJ, Smith AL, Huang YT, Siedlak G, Perry G. Latent infection with cytomegalovirus in Alzheimer's disease (AD): Serum antibody and immunocytochemical studies. Society for Neuroscience, New Orleans LA, November 1997. Society for Neuroscience Abstracts 23:563
  35. Smith AL, Cole R, Smyth KA, Koss E, Lerner AJ, Rowland DY, Debanne SM, Petot GJ, Teel WB, Friedland RP. The protective effects of physical exercise on the development of Alzheimer's disease..Fiftieth annual meeting of the American Academy of Neurology, Minneapolis, MN, April 1998. *Neurology* 1998 *Neurology* 50 (4): A89-90.
  36. Teel WB, Farrer LA, Cupples LA Debanne SM, Koss E, Lerner AJ, Rowland DY, Smith AL, Cole R, Smyth KA, Friedland RP and the MIRAGE study group. Duration of survival after onset of Alzheimer's disease is not affected by smoking status in two epidemiologic studies. International conference on Alzheimer's Disease and associated disorders, Amsterdam, Netherlands, July 1998.
  37. Petot GJ, Riedel TM, Cole R, Debanne SM, Koss E, Lerner AJ, Smyth KA, Whitehouse PJ, Friedland RP. Long-term dietary intake patterns influence the development of Alzheimer's disease in a case control study of lifestyle risk factors. International Conference on Alzheimer's Disease and Associated Disorders, Amsterdam, Netherlands, July 1998
  38. Koss E, Cole R, Gilmore GC, Debanne SM, Lerner AJ, Petot GJ, Riedel TM, Smith AL, Smyth KA, Strauss ME, Teel W, Whitehouse PJ, Friedland RP. Relation between cognition and personality in healthy older adults. International Conference on Alzheimer's Disease and Associated Disorders, Amsterdam, Netherlands, July 1998.
  39. Koss E, LaManna J, Mohamed S, Lindsey R, Lerner A, Gorodeski G. Near Infrared Spectroscopy: A sensitive and reliable measure of vascular changes. Society for Neuroscience Meeting, Los Angeles, CA, 1998
  40. Koss E, Cook TB, Cole R, Debanne S, Petot GJ, Lerner AJ, Smyth KA, Friedland RP. Occupational lead exposure is a risk factor for Alzheimer's disease: A case-Control study. Presented at the Role of Human exposure assessment in the prevention of environmental disease meeting Bethesda MD, September 22, 1999
  41. Lerner AJ, Mizrahi EH, Chen CH, Eckman C, Younkin S, Siavalas EL, Koss E, Petot GA, Smyth KA, Debanne SM, Cook TB, Elston RC, Friedland RP. Relationship of plasma amyloid beta fragments to serum cholesterol, high density lipoprotein, albumin and Apolipoprotein E genotype. 52<sup>nd</sup> annual meeting of the American Academy of Neurology, San Diego, CA, May 2000.
  42. Koss E, Cook TB, Cole R, Debanne SM, Lerner AJ, Petot GA, Smyth KA, Friedland RP. Occupational lead exposure is a risk factor for Alzheimer's disease: A case-control study. 52<sup>nd</sup> annual meeting of the American Academy of Neurology, San Diego, CA, May 2000
  43. Friedland RP, Fritsch T, Smyth K, Koss E, Lerner AJ, Chen CH, Petot G, Debanne SM. Participation in nonoccupational activities in mid-life is protective against the development of Alzheimer's disease: Results from a case-control study. 52<sup>nd</sup> annual meeting of the American Academy of Neurology, San Diego, CA, May 2000.
  44. Mizrahi EH, Jacobsen DW, Lerner AJ, Cook TB, Soas AH, Petot GJ, Koss E, Chen CH, Kapur V, Friedland RP. Plasma total homocysteine (tHcy) and dietary vitamin B6 and Folic acid in Alzheimer's disease and healthy aging. Society for Neuroscience Meeting, New Orleans, LA, November 2000.

45. Mizrahi EH, Fritsch T, Geldmacher DS, Friedland RP, Lerner AJ. Medication utilization in Alzheimer disease and healthy Aging: results from a research registry. World Alzheimer Congress 2000, Washington DC, July 2000
46. Lerner AJ, Mizrahi EH, Chen CH, Younkin S, Cook TC, Friedland RP: Relationship of plasma amyloid beta fragments to serum cholesterol, HDL, Albumin and ApoE genotype. World Alzheimer Congress 2000, Washington DC, July 2000
47. Petot GP, Cook TC, Debanne SM, Koss E, Lerner AJ, Chen CH, Riedel T, Proper D, Smyth KA, Friedland RP: High fat diets during adulthood increase risk for Alzheimer's disease for those with Apo E epsilon-4 allele. World Alzheimer Congress 2000, Washington DC, July 2000
48. Fritsch T, McClendon MJ, Smyth KA, Koss E, Lerner AJ, Chen CH, Petot G, Debanne SM, Friedland RP. The relationship ethnicity, gender, education, occupational status, and age at symptom onset in Alzheimer's disease. Gerontological Society of America, Philadelphia, November 2000
49. Mizrahi EH, Bowirrat A, Korczyn AD, Jacobsen DW, Traore F, Petot GJ, Soas AH, Lerner AJ, Chen CH, Friedland RP. Homocysteine metabolism in Alzheimer disease patients and healthy controls in North America and Israel. Society for Neuroscience, San Diego, CA, November 2001
50. Friedland RP, Farrer LA, Lerner AJ, Soas AH, Debanne SM, Petot GJ, Traore F, Bowirrat A, Jacobsen DW, Younkin SG, Graff-Radford N, Chen C, Korczyn AD. Gene-environment interactions and the causal web of Alzheimer's disease: Implications for drug studies. Fifth International Conference on Progress in Alzheimer's and Parkinson's disease. Kyoto, Japan, April 5, 2001
51. Ubogu E, Reed D, Sagar S, Lerner A, Maddux B, Suarez J, Werz MA. Ketamine for refractory status epilepticus: A case of suspected ketamine-induced neurotoxicity. American Epilepsy Society / American Clinical Neurophysiology Society Meeting, December 2001. *Epilepsia* 42 (Suppl 7):147-8, 2001
52. Arvanitakis Z, Lucas JA, Lerner AJ, Friedland RP, Younkin LH, Younkin SG, Graff-Radford NR. Amyloid  $\beta$  protein plasma levels correlate with serum cholesterol parameters in ApoE4 negative Alzheimer's disease patients and controls. American Neurological Association, Chicago, IL, October 2001
53. Mizrahi E, Bowirrat A, Korczyn A, Jacobsen D, Traore F, Petot G, Lerner A, Debanne S, Adunsky A, Friedland R. Plasma total homocysteine, Vitamin B12 and folate levels in Alzheimer's disease and healthy aged controls in Arabs residing in Israel. 8th International Alzheimer's Disease Congress, Stockholm, Sweden July 2002
54. Lerner A, Friedland RP, McClendon MJ, Auchus AP. Comparison of demographics and referral source of African-American (AA) cases and controls in a longitudinal study of Alzheimer's disease. Presented at Alzheimer's Association 10<sup>th</sup> International Conference on Alzheimer's disease and related disorders, Madrid, Spain July 2006. *Alzheimer's and Dementia* 2(3):suppl 1, 146, 2006.
55. Geldmacher DS, Fritsch T, McClendon MJ, Lerner AJ, Landreth GE. A double-blind, placebo-controlled, 18-month pilot study of the PPAR-Gamma agonist Pioglitazone in Alzheimer's disease. Presented at Alzheimer's Association 10<sup>th</sup> International Conference on Alzheimer's disease and related disorders, Madrid, Spain July 2006. *Alzheimer's and Dementia* 2(3):suppl 1, 366, 2006.
56. Lerner AJ, McClendon MJ. Receiver-Operator characteristics (ROC) of the mini-mental state examination(MMSE) relative to the clinical dementia rating (CDR) scale Presented at Alzheimer's Association 10<sup>th</sup> International Conference on Alzheimer's disease and related disorders, Madrid, Spain July 2006. *Alzheimer's and Dementia* 2(3):suppl 1, 391, 2006.
57. Goodenowe DB, Cook LL, Liu J, Lu Y, Jayasingh DA, Ahioono PWK, Heath D, Yamazaki Y, Wood PL, Krenitsky KF, Sparks DL, Lerner A, Friedland RP, Kudo T, Kamino K, Morihara T, Takeda M, Flax J Serum Ethanolamine Plasmalogen Levels Correlate with Alzheimer's Pathology and Severity of Dementia. Presented at Biomarkers in Alzheimer's disease. Washington D.C. June 11, 2007.
58. Lerner AJ, Ogrocki PK, Thomas PJ. A network graph analysis of category fluency data. American Academy of Neurology, Chicago, IL April 16, 2008
59. Costaldi ME, Grommes C, Rajappanair L, Lerner AJ, Taylor HL, Downes KA. Use of therapeutic plasma exchange for anti-thyroid antibody removal in Hashimoto's encephalopathy (steroid responsive encephalopathy associated with autoimmune thyroiditis). American Society for Apheresis, Galveston, TX, April 2008
60. Grommes C, Griffin C, Downes KA, Lerner A. Diffusion MRI changes and the clinical course of steroid responsive encephalopathy. American Academy of Neurology, Chicago IL, April 2008
61. Bernitsas E, Horn C, Miller DW, Lerner AJ. Prolonged cognitive dysfunction after recurrent hypoglycemia. American Academy of Neurology, Chicago IL, April 2008
62. Giuffrida JP, Lerner A, Steiner R, Daly J. Upper Extremity Stroke Therapy Task Discrimination Using Motion Sensors and Electromyography. American Academy of Neurology, Chicago IL, April 2008
63. Herrup K, Cohen M, Lerner AJ, Yang Y. Cell Cycle Events Implicate Cerebellar Dentate Nucleus Neurons As Targets Of Alzheimer's Pathology. 11<sup>th</sup> International conference on Alzheimer's disease. Chicago, IL July

2008

64. Lerner AJ, Sami S, Albo Z. Mapping of Alzheimer Disease Stages Using The MMSE: Effects Of Ethnicity And Education. 11<sup>th</sup> International conference on Alzheimer's disease. Chicago, IL July 2008
65. Lerner AJ, Albo Z, Singh T, Messer J, Woczynczki W. Alzheimer's disease as descent into randomness: Evidence from category fluency. Society for Neuroscience, Washington, D.C. November 2008
66. Lerner AJ, Wen H, Jaeger J, Tatsuoka C. Predicting conversion from MCI to AD using partially ordered models of cognitive functioning. ADNI Meeting, Seattle, WA April 2009
67. Lerner AJ, Messer J, Singh T, Leverenz J, Zabetian, C, Thomas PJ, Woczyński, WA. Using category fluency data to create phylogenetic trees of cognitive phenotypes. American Academy of Neurology, Seattle WA April 2009
68. Lerner AJ, Hernandez S, Smyth KA, McClendon M. Usage of Pharmacological Treatments for Alzheimer's disease: Associations of Race and Demographic Variables. American Academy of Neurology, Seattle WA April 2009
69. Gustaw-Rothenberg K, Siedlak SL, Lerner A, Smith MA. Newly diagnosed Alzheimer's disease patients show increased dissociated A $\beta$  antibody levels. American Association of Neuropathologists 85<sup>th</sup> annual meeting, San Antonio, TX June 2009. *J Neuropathology and Experimental Neurology* 68:569 (2009)
70. Meyer D, Woczyński WA, Thomas PJ, Singh T, Lerner AJ. Mathematical analysis of cognitive output of Alzheimer's disease. Society for Mathematical Biology, Vancouver, BC July 2009.

#### Other Publications

1. Lerner AJ. What the hands reveal about the brain. (Book review), *Neurology* 40:1806, 1991
2. Lerner AJ, Friedland RP, Whitehouse PJ. Uses of biological markers. Editorial, *Alzheimer's Disease and Associated Disorders* 6 (4): 197 - 200, 1992.
3. Lerner AJ. Dementia and Normal Aging (book review). *Neurology* 45:1036
4. Lerner AJ, Friedland RP. The evolution of Alzheimer's Disease. (Essay / book review), *The Gerontologist*, October 1996, 36:713 – 714
5. Debanne SM, Rowland DY, Friedland RP, Lerner A. Smoking and Alzheimer's disease. Letter to the editor (reply). *Lancet*, 1997
6. Hinze SW, Gaines AD, Lerner AJ, Whitehouse PJ. Women and Alzheimer's Disease: A response (Editorial). *Alzheimer's Disease and Associated Disorders* 1999.
7. Cole, M, Lerner AJ: Dyslexia in Hebrew. Letter to the Editor. *Journal of Neurology, Neurosurgery and Psychiatry* 68: 537-538, 2000
8. Lerner AJ. Treatment of pica behavior with olanzapine. *Psychiatric weekly*. October 1, 2007 2(37).
9. Lerner, AJ. Plum and Posner's Diagnosis of Stupor and Coma. *Critical Care Medicine*. 36(8): 2492, August 2008.